23 results on '"Purdie, D"'
Search Results
2. Epithelial ovarian carcinoma and fertility of parents.
- Author
-
Siskind V, Purdie D, Whiteman D, and Green A
- Subjects
- Carcinoma genetics, Female, Humans, Middle Aged, Ovarian Neoplasms genetics, Reproductive History, Risk Factors, Carcinoma etiology, Fertility, Ovarian Neoplasms etiology, Parents
- Published
- 2002
- Full Text
- View/download PDF
3. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
- Author
-
Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM, and Chenevix-Trench G
- Subjects
- Adult, Age Factors, Australia epidemiology, Breast Neoplasms epidemiology, Breast Neoplasms etiology, Case-Control Studies, Female, Genotype, Humans, Menopause, Middle Aged, Ovarian Neoplasms epidemiology, Ovarian Neoplasms etiology, Risk Factors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase genetics, Breast Neoplasms genetics, Genetic Predisposition to Disease, Ovarian Neoplasms genetics, Polymorphism, Genetic
- Abstract
The enzyme 5alpha-reductase type II (SRD5A2) converts testosterone to its more active form 5alpha-dihydroxytestosterone. The 3' untranslated region of the gene contains a (TA)(n) length polymorphism. The (TA)(9) allele has been reported to be associated with higher serum prostate-specific antigen levels in breast tumors and lower risk of relapse in breast cancer patients and more recently has also been reported to be linked to the codon 89 valine variant, which is itself associated with higher serum prostate-specific antigen levels in breast tumors and a more favorable breast cancer prognosis. We investigated whether the SRD5A2 (TA)(n) polymorphism was associated with risk of breast or ovarian cancer in Australian women by studying 946 breast cancer cases and 509 age-matched controls, and 544 ovarian cancer cases and 298 controls of similar age distribution. The (TA)(9) allele frequency was similar in breast cancer cases (0.110), breast cancer controls (0.125), ovarian cancer cases (0.106), and ovarian cancer controls (0.117). There was no difference in genotype distribution between breast cancer cases and controls (P = 0.5), ovarian cancer cases and controls (P = 0.7), or between the two control groups (P = 0.9). Genotypes containing at least one (TA)(9) allele were not significantly associated with risk of breast cancer overall (odds ratio, 0.86; 95% confidence interval, 0.67-1.12; P = 0.3) or in women stratified by age, menopausal status, or family history. Similarly, the (TA)(9) allele was not associated with risk of ovarian cancer (odds ratio, 0.87; 95% confidence interval, 0.61-1.23; P = 0.4) or with ovarian tumor behavior (invasive or low malignant potential), histology, stage, or grade. Given that this study had sufficient power to detect altered risks in the order of 1.4- to 1.7-fold, our results suggest that the SRD5A2 (TA)(9) allele is unlikely to be associated with moderate alterations in breast or ovarian cancer risk.
- Published
- 2001
4. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas.
- Author
-
Arnold JM, Cummings M, Purdie D, and Chenevix-Trench G
- Subjects
- Adenocarcinoma pathology, Antimetabolites, Antineoplastic pharmacology, Azacitidine pharmacology, DNA Primers, Down-Regulation, Female, Humans, Intercellular Adhesion Molecule-1 genetics, Loss of Heterozygosity, Methylation, Oligonucleotide Array Sequence Analysis, Ovarian Neoplasms pathology, Prognosis, RNA, Messenger analysis, Survival Analysis, Tumor Cells, Cultured, Adenocarcinoma genetics, DNA, Neoplasm genetics, Gene Expression Regulation, Neoplastic, Intercellular Adhesion Molecule-1 biosynthesis, Ovarian Neoplasms genetics
- Abstract
Ovarian adenocarcinomas develop as the result of multiple genetic and epigenetic changes in the precursor ovarian surface epithelial (OSE) cells which result in a malignant phenotype. We investigated changes in gene expression in ovarian adenocarcinoma using a cDNA array containing 588 known human genes. We found that intercellular adhesion molecule-1 (ICAM-1) was expressed at lower levels in the ovarian tumour cell lines OAW42, PEO1 and JAM than in the immortalised human ovarian surface epithelial cell line HOSE 17.1. Further investigation revealed ICAM-1 was expressed in the surface epithelium of normal ovaries and both mRNA and protein expression levels were reduced in the majority of ovarian adenocarcinoma cell lines and primary tumours. ICAM-1 expression was increased in 8/8 cell lines treated with the de novo methyltransferase inhibitor 5-aza-2'-deoxycytidine, indicating that methylation of CpG islands may play a role in the down-regulation of its expression in primary tumours. There was a significant association between patients whose tumours expressed ICAM-1 and survival (P = 0.03), suggesting that expression levels of ICAM-1 may have clinical relevance., (Copyright 2001 Cancer Research Campaign)
- Published
- 2001
- Full Text
- View/download PDF
5. Body size and ovarian cancer: case-control study and systematic review (Australia).
- Author
-
Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, and Green AC
- Subjects
- Adolescent, Adult, Aged, Australia epidemiology, Body Mass Index, Case-Control Studies, Female, Humans, Middle Aged, Odds Ratio, Body Constitution, Ovarian Neoplasms epidemiology
- Abstract
Objective: Although increased body mass is an established risk factor for a variety of cancers, its relation with cancer of the ovary is unclear. We therefore investigated the association between measures of body mass index (BMI) and ovarian cancer risk., Methods: Data from an Australian case-control study of 775 ovarian cancer cases and 846 controls were used to examine the association with BMI. We have also summarized the results from a number of other studies that have examined this association., Results: There was a significant increased risk of ovarian cancer with increasing BMI, with women in the top 15% of the BMI range having an odds ratio (OR) of 1.9 (95% confidence interval (CI), 1.3-2.6) compared with those in the middle 30%. Stratifying by physical activity showed a stronger effect among inactive women (OR = 3.0, 95% CI 1.3-6.9). The overall effect was consistent with the findings of most prior population-based case-control studies, while cohort studies reported positive effects closer to the null. Hospital-based studies gave variable results., Conclusions: Taken together, the evidence is in favor of a small to moderate positive relation between high BMI and occurrence of ovarian cancer.
- Published
- 2001
- Full Text
- View/download PDF
6. Cigarette smoking and risk of epithelial ovarian cancer (Australia).
- Author
-
Green A, Purdie D, Bain C, Siskind V, and Webb PM
- Subjects
- Adenocarcinoma, Mucinous epidemiology, Adolescent, Adult, Aged, Australia epidemiology, Case-Control Studies, Confidence Intervals, Female, Humans, Middle Aged, Odds Ratio, Ovarian Neoplasms epidemiology, Risk Factors, Adenocarcinoma, Mucinous etiology, Ovarian Neoplasms etiology, Smoking adverse effects
- Abstract
Objectives: We studied the association between cigarette smoking and ovarian cancer in a population-based case control study., Methods: A total of 794 women with histologically confirmed epithelial ovarian cancer who were aged 18-79 years and resident in one of three Australian states were interviewed, together with 855 controls aged 18-79 years selected at random from the electoral roll from the same states. Information was obtained about cigarette smoking and other factors including age, parity, oral contraceptive use, and reproductive factors. We estimated the relative risk of ovarian cancer associated with cigarette smoking, accounting for histologic type, using multivariable logistic regression to adjust for confounding factors., Results: Women who had ever smoked cigarettes were more likely to develop ovarian cancer than women who had never smoked (adjusted odds ratio (OR) = 1.5; 95% confidence interval (CI) = 1.2-1.9). Risk was greater for ovarian cancers of borderline malignancy (OR = 2.4; 95% CI = 1.4-4.1) than for invasive tumors (OR = 1.7; 95% CI = 1.2-2.4) and the histologic subtype most strongly associated overall was the mucinous subtype among both current smokers (OR = 3.2; 95% CI = 1.8-5.7) and past smokers (OR = 2.3; 95% CI = 1.3-3.9)., Conclusions: These data extend recent findings and suggest that cigarette smoking is a risk factor for ovarian cancer, especially mucinous and borderline mucinous types. From a public health viewpoint, this is one of the few reports of a potentially avoidable risk factor for ovarian cancer.
- Published
- 2001
- Full Text
- View/download PDF
7. Ovarian lymphangioma: MRI appearances.
- Author
-
Kearney CE, Hall GH, Purdie DW, and Turnbull LW
- Subjects
- Female, Humans, Middle Aged, Lymphangioma diagnosis, Magnetic Resonance Imaging, Ovarian Neoplasms diagnosis
- Published
- 2001
- Full Text
- View/download PDF
8. Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer.
- Author
-
Purdie DM, Siskind V, Bain CJ, Webb PM, and Green AC
- Subjects
- Adolescent, Adult, Age Distribution, Aged, Australia epidemiology, Carcinoma classification, Case-Control Studies, Causality, Comorbidity, Contraceptives, Oral, Female, Humans, Logistic Models, Middle Aged, Multivariate Analysis, Odds Ratio, Ovarian Neoplasms classification, Postmenopause, Premenopause, Risk Factors, Breast Neoplasms epidemiology, Carcinoma epidemiology, Neoplasms, Cystic, Mucinous, and Serous epidemiology, Ovarian Neoplasms epidemiology, Reproductive History
- Abstract
The proposition that mucinous ovarian cancer has an etiology distinct from that of other histologic types has been evaluated using data from a population-based case-control study of epithelial ovarian cancer conducted in 1990--1993 among Australian women aged 18--79 years. The protective effects of parity and oral contraceptive use were greater in nonmucinous than in mucinous ovarian tumors. However, these differences appeared to be driven largely by the effect of ovulatory life, which was positively associated with nonmucinous tumors only. An association with family history of breast and/or ovarian cancer also appeared to be restricted to nonmucinous cancers. These results lend support to the hypothesis that mucinous and nonmucinous ovarian tumors develop via different causal mechanisms.
- Published
- 2001
- Full Text
- View/download PDF
9. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.
- Author
-
Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, and Chenevix-Trench G
- Subjects
- Base Sequence, Case-Control Studies, DNA Primers, Female, Genetic Heterogeneity, Humans, Odds Ratio, Exons, Leucine genetics, Ovarian Neoplasms genetics, Point Mutation, Polymorphism, Genetic, Receptors, Progesterone genetics, Valine genetics
- Abstract
Epidemiological studies suggest that ovarian cancer is an endocrine-related tumour, and progesterone exposure specifically may decrease the risk of ovarian cancer. To assess whether the progesterone receptor (PR) exon 4 valine to leucine amino acid variant is associated with specific tumour characteristics or with overall risk of ovarian cancer, we examined 551 cases of epithelial ovarian cancer and 298 unaffected controls for the underlying G-->T nucleotide substitution polymorphism. Stratification of the ovarian cancer cases according to tumour behaviour (low malignant potential or invasive), histology, grade or stage failed to reveal any heterogeneity with respect to the genotype defined by the PR exon 4 polymorphism. Furthermore, the genotype distribution did not differ significantly between ovarian cancer cases and unaffected controls. Compared with the GG genotype, the age-adjusted odds ratio (95% confidence interval) for risk of ovarian cancer was 0.78 (0.57-1.08) for the GT genotype, and 1.39 (0.47-4.14) for the TT genotype. In conclusion, the PR exon 4 codon 660 leucine variant encoded by the T allele does not appear to be associated with ovarian tumour behaviour, histology, stage or grade. This variant is also not associated with an increased risk of ovarian cancer, and is unlikely to be associated with a large decrease in ovarian cancer risk, although we cannot rule out a moderate inverse association between the GT genotype and ovarian cancer.
- Published
- 2001
- Full Text
- View/download PDF
10. Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas.
- Author
-
Arnold JM, Mok SC, Purdie D, and Chenevix-Trench G
- Subjects
- Adenocarcinoma metabolism, Adenocarcinoma pathology, Blotting, Northern, Blotting, Western, Cell Line, Transformed, Cells, Cultured, DNA Mutational Analysis, DNA, Neoplasm chemistry, DNA, Neoplasm genetics, Female, Gene Expression Regulation, Neoplastic, Humans, Inhibitor of Differentiation Proteins, Loss of Heterozygosity, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Polymorphism, Single-Stranded Conformational, RNA, Neoplasm genetics, RNA, Neoplasm metabolism, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors metabolism, Tumor Cells, Cultured, Adenocarcinoma genetics, Chromosomes, Human, Pair 1 genetics, Neoplasm Proteins, Ovarian Neoplasms genetics, Transcription Factors genetics
- Abstract
The molecular events that drive the initiation and progression of ovarian adenocarcinoma are not well defined. We have investigated changes in gene expression in ovarian cancer cell lines compared to an immortalized human ovarian surface epithelial cell line (HOSE) using a cDNA array. We identified 17 genes that were under-expressed and 10 genes that were over-expressed in the cell lines compared to the HOSE cells. One of the genes under-expressed in the ovarian cancer cell lines, Id3, a transcriptional inactivator, was selected for further investigation. Id3 mRNA was expressed at reduced levels in 6 out of 9 ovarian cancer cell lines compared to the HOSE cells while at the protein level, all 7 ovarian cancer cell lines examined expressed the Id3 protein at greatly reduced levels. Expression of Id3 mRNA was also examined in primary ovarian tumours and was found in only 12/38 (32%) cases. A search was conducted for mutations of Id3 in primary ovarian cancers using single stranded conformation polymorphism (SSCP) analysis. Only one nucleotide substitution, present also in the corresponding constitutional DNA, was found in 94 ovarian tumours. Furthermore no association was found between LOH at 1p36 and lack of expression of Id3. These data suggest that Id3 is not the target of LOH at 1p36.
- Published
- 2001
- Full Text
- View/download PDF
11. The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer.
- Author
-
Spurdle AB, Purdie DM, Webb PM, Chen X, Green A, and Chenevix-Trench G
- Subjects
- Adult, Aged, Base Sequence, Case-Control Studies, DNA Primers, Epoxide Hydrolases chemistry, Female, Genotype, Humans, Middle Aged, Ovarian Neoplasms enzymology, Epoxide Hydrolases genetics, Histidine genetics, Microsomes enzymology, Ovarian Neoplasms genetics, Polymorphism, Genetic, Tyrosine genetics
- Abstract
Functional significance has been demonstrated in vitro for the exon 3 T-->C Tyr113His amino acid substitution polymorphism of the microsomal epoxide hydrolase (EPHX) gene. The higher activity or fast TT genotype was previously reported to be associated with an increased risk of ovarian cancer, and this association may reflect enhanced activation of endogenous or exogenous substrates to more reactive and mutagenic derivatives. Components of cigarette smoke are examples of exogenous substrates subject to such bioactivation, and smoking exposure may thus modify the risk associated with the EPHX polymorphism. We examined 545 cases of epithelial ovarian cancer and 287 unaffected controls for this EPHX T-C genetic variant to investigate whether, in the Australian population, the TT genotype was associated with (i) specific ovarian tumor characteristics; (ii) risk of ovarian cancer, overall or for specific subgroups; and (iii) risk of ovarian cancer in smokers specifically. Genotyping was carried out using the Perkin-Elmer ABI Prism 7700 Sequence Detection System for fluorogenic polymerase chain reaction allelic discrimination. Stratification of the ovarian cancer cases according to tumor behavior (low malignant potential or invasive), grade, stage, and p53 immunohistochemical status failed to show any heterogeneity with respect to the genotype defined by the EPHX polymorphism. There was a suggestion of heterogeneity with respect to histologic subtype (P=0.03), largely due to a decreased frequency of the TT genotype in endometrioid tumors. EPHX genotype distribution did not differ significantly between unaffected controls and ovarian cancer cases (overall, low malignant potential, or invasive) either overall or after stratification by smoking status. However, the TT genotype was associated with a decreased risk of invasive ovarian cancer of the endometrioid subtype specifically (age-adjusted odds ratio=0.38, 95% confidence interval=0.17-0.87). The results suggest that the proposed EPHX-mediated bioactivation of components of cigarette smoke to mutagenic forms is unlikely to be involved in the etiology of ovarian cancer in general but that a greater rate of EPHX-mediated detoxification may decrease the risk of endometrioid ovarian cancer. Mol. Carcinog. 30:71-78, 2001., (Copyright 2001 Wiley-Liss, Inc.)
- Published
- 2001
- Full Text
- View/download PDF
12. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype.
- Author
-
Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, and Chenevix-Trench G
- Subjects
- Adenocarcinoma, Clear Cell enzymology, Adenocarcinoma, Clear Cell genetics, Adenocarcinoma, Clear Cell pathology, Adult, Aged, Aged, 80 and over, Carcinoma, Endometrioid enzymology, Carcinoma, Endometrioid genetics, Carcinoma, Endometrioid pathology, Case-Control Studies, Epithelium pathology, Female, Genetic Predisposition to Disease, Genotype, Glutathione S-Transferase pi, Humans, Isoenzymes genetics, Middle Aged, Ovarian Neoplasms enzymology, Risk Factors, Tumor Suppressor Protein p53 biosynthesis, Glutathione Transferase genetics, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Polymorphism, Genetic
- Abstract
The phase II glutathione S-transferases (GSTs) GSTT1, GSTM1 and GSTP1 catalyse glutathione-mediated reduction of exogenous and endogenous electrophiles. These GSTs have broad and overlapping substrate specificities and it has been hypothesized that allelic variants associated with less effective detoxification of potential carcinogens may confer an increased susceptibility to cancer. To assess the role of GST gene variants in ovarian cancer development, we screened 285 epithelial ovarian cancer cases and 299 unaffected controls for the GSTT1 deletion (null) variant, the GSTM1 deletion (null) variant and the GSTP1 codon 104 A-->G Ile-->Val amino acid substitution variant. The frequencies of the GSTT1, GSTM1 and GSTP1 polymorphic variants did not vary with tumour behaviour (low malignant potential or invasive) or p53 immunohistochemical status. There was a suggestion that ovarian cancers of the endometrioid or clear cell histological subtype had a higher frequency of the GSTT1 and GSTM1 deletion genotype than other histological subgroups. The GSTT1, GSTM1 and GSTP1 genotype distributions did not differ significantly between unaffected controls and ovarian cancer cases (overall or invasive cancers only). However, the GSTM1 null genotype was associated with increased risk of endometrioid/clear cell invasive cancer [age-adjusted OR (95% CI) = 2.04 (1.01-4.09), P = 0.05], suggesting that deletion of GSTM1 may increase the risk of ovarian cancer of these histological subtypes specifically. This marginally significant finding will require verification by independent studies.
- Published
- 2001
- Full Text
- View/download PDF
13. Multiple births and risk of epithelial ovarian cancer.
- Author
-
Whiteman DC, Murphy MF, Cook LS, Cramer DW, Hartge P, Marchbanks PA, Nasca PC, Ness RB, Purdie DM, and Risch HA
- Subjects
- Adenocarcinoma, Mucinous epidemiology, Adult, Aged, Australia epidemiology, Carcinoma etiology, Case-Control Studies, Female, Humans, Logistic Models, Middle Aged, Odds Ratio, Ontario epidemiology, Ovarian Neoplasms etiology, Risk, United States epidemiology, Carcinoma epidemiology, Multiple Birth Offspring, Ovarian Neoplasms epidemiology
- Abstract
Background and Methods: Prevailing hypotheses about the causes of ovarian carcinogenesis predict that women with a history of multiple births (twins, triplets, etc.) should be at increased risk of epithelial ovarian cancer. However, the scant available evidence suggests that they may actually be at lower risk. To resolve this issue, we pooled data from eight studies involving 2859 parous women with epithelial ovarian cancer (case patients) and 7434 parous women without ovarian cancer (control women). In addition to assessing their history of multiple births (and the sex of the children, where available), we obtained information on age, parity, oral contraceptive use, and other reproductive factors for each woman. Details of tumor histology were available for all case patients. We estimated the relative risks of various histologic types of ovarian cancers associated with multiple births by using multivariable logistic regression analysis, adjusting for matching and confounding variables., Results: Among these parous women, 73 case patients (2. 6%) and 257 control women (3.5%) had a history of multiple births. The adjusted summary odds ratio (OR) for developing all types of epithelial ovarian cancer that are associated with multiple births was 0.81 (95% confidence interval [CI] = 0.61-1.08). We found no evidence that risks associated with multiple births differed among women with borderline or invasive tumors and among women with same-sex and opposite-sex offspring from multiple births. The risk reductions appeared specific for nonmucinous tumors (n = 2453; summary adjusted OR = 0.71 [95% CI = 0.52-0.98]); in contrast, associations with mucinous tumors (n = 406) were heterogeneous across studies., Conclusions: Parous women with nonmucinous ovarian cancer are no more likely to have a history of multiple births than other parous women, counter to the predictions of current hypotheses for causes of ovarian cancer.
- Published
- 2000
- Full Text
- View/download PDF
14. Beyond ovulation: oral contraceptives and epithelial ovarian cancer.
- Author
-
Siskind V, Green A, Bain C, and Purdie D
- Subjects
- Adult, Aged, Australia, Body Mass Index, Carcinoma pathology, Case-Control Studies, Contraceptives, Oral administration & dosage, Female, Humans, Hysterectomy, Linear Models, Middle Aged, Ovarian Neoplasms pathology, Ovulation drug effects, Parity, Registries, Carcinoma prevention & control, Contraceptives, Oral therapeutic use, Ovarian Neoplasms prevention & control, Ovulation physiology
- Abstract
In a case-control study in three Australian states that included 794 women with epithelial ovarian cancer and 853 community controls for whom we had adequate contraceptive and reproductive histories, we examined the effects of oral contraceptive use after controlling for estimated number of ovulatory cycles. Other covariates included in the multiple logistic regression analysis were parity, smoking, and history of pelvic surgery. The protective effect of duration of oral contraceptive use appeared to be multiplicative, with a 7% decrease in relative risk per year [95% confidence interval (CI) = 4-9%], persisting beyond 15 years of exposure. Use for up to 1 year may have a greater effect than predicted (odds ratio = 0.57; 95% CI = 0.40-0.82), whereas use before the first pregnancy may be additionally beneficial (odds ratio = 0.95; 95% CI = 0.87-1.03, adjusted for overall duration of use). Better control for ovulatory life might attenuate these estimates somewhat. There was little evidence of waning protection with time since last exposure or of extra benefit with early commencement of oral contraceptive use. We found no convincing evidence of effect modification in any factor examined or differences in effect among the three main histologic cancer types or between borderline and malignant tumors. Oral contraceptives may act by both suppressing ovulation and altering the tumor-promoting milieu.
- Published
- 2000
- Full Text
- View/download PDF
15. Hormone replacement therapy and risk of epithelial ovarian cancer.
- Author
-
Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, Quinn MA, and Green AC
- Subjects
- Adenocarcinoma chemically induced, Adenocarcinoma, Clear Cell chemically induced, Adenocarcinoma, Clear Cell epidemiology, Adult, Aged, Carcinoma, Endometrioid chemically induced, Case-Control Studies, Drug Interactions, Estrogens administration & dosage, Estrogens adverse effects, Estrogens pharmacology, Female, Humans, Hysterectomy statistics & numerical data, Incidence, Middle Aged, Mixed Tumor, Mesodermal chemically induced, Mixed Tumor, Mesodermal epidemiology, Mixed Tumor, Mullerian chemically induced, Mixed Tumor, Mullerian epidemiology, New South Wales epidemiology, Odds Ratio, Ovarian Neoplasms chemically induced, Postmenopause, Postoperative Complications chemically induced, Postoperative Complications epidemiology, Progestins administration & dosage, Progestins adverse effects, Progestins pharmacology, Queensland epidemiology, Risk, Sterilization, Tubal statistics & numerical data, Victoria epidemiology, Adenocarcinoma epidemiology, Carcinoma, Endometrioid epidemiology, Hormone Replacement Therapy adverse effects, Ovarian Neoplasms epidemiology
- Abstract
It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case-control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type, was examined. A total of 793 eligible incident cases of epithelial ovarian cancer diagnosed from 1990 to 1993 among women living in Queensland, New South Wales and Victoria were identified. These were compared with 855 eligible female controls selected at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed reproductive and contraceptive histories, as well as details about hormone replacement therapy and pelvic operations. No clear associations were observed between use of hormone replacement therapy overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32-4.94). In addition, the risk associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% CI 1.54-5.85) than in those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian tumours.
- Published
- 1999
- Full Text
- View/download PDF
16. Milk consumption, galactose metabolism and ovarian cancer (Australia).
- Author
-
Webb PM, Bain CJ, Purdie DM, Harvey PW, and Green A
- Subjects
- Adolescent, Adult, Aged, Animals, Australia epidemiology, Case-Control Studies, Dairy Products, Female, Humans, Middle Aged, Odds Ratio, Ovarian Neoplasms etiology, Risk Factors, Surveys and Questionnaires, UTP-Hexose-1-Phosphate Uridylyltransferase blood, Dietary Fats administration & dosage, Dietary Fats adverse effects, Galactose metabolism, Milk adverse effects, Ovarian Neoplasms epidemiology
- Abstract
Objectives: It has been suggested that increased exposure to galactose, due to high consumption of dairy foods or reduced galactose metabolism, is associated with the development of ovarian cancer. We have investigated this in a large case-control study conducted in three Australian states between 1990 and 1993., Methods: Approximately 800 histologically-confirmed cases, 800 community controls and 300 controls recruited through breast-screening clinics completed dietary questionnaires. Approximately 100 cases and all breast-screening controls also provided a blood sample for analysis of galactose-1-phosphate-uridyltransferase (GALT)., Results: Ovarian cancer risk was positively associated with increasing consumption of whole milk and other full-fat dairy foods, but was not associated with consumption of low-fat dairy foods and was inversely related to consumption of skimmed milk. There was no association between ovarian cancer and GALT except among women with abnormally low GALT who had a non-significant 2.5-fold increased risk of ovarian cancer., Conclusions: These data do not support the hypothesis that galactose plays a major role in the development of ovarian cancer and suggest that reported associations between milk consumption and ovarian cancer are due to the fat content of milk and not to lactose or galactose. An increased risk of ovarian cancer in women with abnormally low levels of GALT cannot, however, be ruled out.
- Published
- 1998
- Full Text
- View/download PDF
17. Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer.
- Author
-
Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, and Chenevix-Trench G
- Subjects
- Adult, Aged, Australia, Carcinoma genetics, Carcinoma pathology, Case-Control Studies, Female, Humans, Middle Aged, Neoplasm Invasiveness, Odds Ratio, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Prevalence, Risk, Risk Factors, Carcinoma etiology, Carcinoma physiopathology, Mutation, Ovarian Neoplasms etiology, Ovarian Neoplasms physiopathology, Ovulation, Tumor Suppressor Protein p53 genetics
- Abstract
Background: It has been suggested that increased numbers of ovulations might increase the risk of p53 gene (also known as TP53) mutation in the ovarian epithelium, thereby leading to the development of cancer. The data supporting this hypothesis have come from an observation that accumulation of p53 protein in epithelial ovarian cancer was strongly associated with increasing numbers of ovulatory cycles. We have further investigated the association between ovulatory history and p53 gene mutation by use of data from a large case-control study of ovarian cancer in Australia., Methods: Tissue blocks were available for immunohistochemical analysis of p53 protein from 234 case subjects, aged 18-79 years, who had invasive epithelial ovarian cancer. Epidemiologic data were also available for these women and for 855 control subjects. Case-case comparisons were made by use of prevalence ratios and 95% confidence intervals (CIs), and case-control comparisons were made by use of odds ratios (ORs) and 95% CIs. All statistical tests were two-sided., Results: There was no association between p53 accumulation and years of ovulation. Women with p53-positive cancers had undergone an average of 29.3 years of ovulation compared with 29.0 years of ovulation for women with p53-negative cancers (P=.8). Although the overall risk of ovarian cancer development was significantly increased in women who had undergone more years of ovulation (OR=2.17; 95% CI =1.54-3.05-for > or =35 years versus <23 years of ovulation), there was no difference in the risk associated with p53-positive and p53-negative cancers., Conclusions: These results confirm the association between increased ovulation and ovarian cancer risk but do not support the hypothesis that this association is due to an increased risk of p53 mutation with a greater number of ovulatory cycles.
- Published
- 1998
- Full Text
- View/download PDF
18. Fertility and incidence of KRAS2 mutations in borderline ovarian adenocarcinomas.
- Author
-
Chenevix-Trench G, Coombs T, Kerr J, Purdie D, Green A, and Cummings MC
- Subjects
- Female, Humans, Incidence, Adenocarcinoma genetics, Adenocarcinoma physiopathology, Fertility, Genes, ras genetics, Mutation, Ovarian Neoplasms genetics, Ovarian Neoplasms physiopathology
- Published
- 1997
- Full Text
- View/download PDF
19. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group.
- Author
-
Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, and Ward B
- Subjects
- Adolescent, Adult, Aged, Australia epidemiology, Case-Control Studies, Female, Humans, Middle Aged, Risk Factors, Hysterectomy, Ovarian Neoplasms epidemiology, Sterilization, Tubal
- Abstract
We have examined the effect of tubal sterilisation and hysterectomy on risk of ovarian cancer in a large case-control study in eastern Australia involving 824 women aged 18-79 years, diagnosed with epithelial ovarian cancer between 1990 and 1993, and 855 controls randomly selected from the electoral roll. Relative risks for ovarian cancer were estimated using multiple categorical regression to adjust for age, parity, oral contraceptive use and other risk factors. Tubal sterilisation was associated with a 39% reduction in risk of ovarian cancer (RR 0.61, 95% CI 0.46-0.85) and hysterectomy with a 36% reduction (RR 0.64, 95% CI 0.48-0.85). Risk remained low 25 years after surgery and was reduced irrespective of sterilisation technique, and estimates were similar among various types of epithelial ovarian cancer. The greatest reduction (74%) was observed among women with primary peritoneal tumours. Pelvic infection and use of vaginal sprays or contraceptive foams were not related to ovarian cancer, while use of talc in the perineal region slightly but significantly increased risk among women with patent fallopian tubes. Reportedly heavy or painful menses, perhaps associated with retrograde flow, were associated with ovarian cancer, and reduction in risk of disease after hysterectomy was greatest among women who had heavy periods. Our findings support the theory that contaminants from the vagina, such as talc, and from the uterus, such as endometrium, gain access to the peritoneal cavity through patent fallopian tubes and may enhance the malignant transformation of ovarian surface epithelium. Surgical tubal occlusion may reduce the risk of ovarian cancer by preventing the access of such agents.
- Published
- 1997
- Full Text
- View/download PDF
20. Validity of self-reported hysterectomy and tubal sterilisation. The Survey of Women's Health Study Group.
- Author
-
Green A, Purdie D, Green L, Dick ML, Bain C, and Siskind V
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Confidence Intervals, Female, Humans, Middle Aged, Reproducibility of Results, Carcinoma etiology, Hysterectomy statistics & numerical data, Memory, Ovarian Neoplasms etiology, Sterilization, Tubal statistics & numerical data, Surveys and Questionnaires standards
- Abstract
Both hysterectomy and tubal sterilisation offer significant protection from ovarian cancer, and the risk of cardiovascular disease in women is lowered after hysterectomy. Since little is known about the accuracy of women's self-reports of these procedures, we assessed their reliability and validity using data obtained in a case-control study of ovarian cancer. There was 100 per cent repeatability for both positive and negative histories of hysterectomy and tubal sterilisation among a small sample of women on reinterview. Verification of surgery was sought against surgeons' or medical records, or if these were unavailable, from randomly selected current general practitioners for 51 cases and 155 controls reporting a hysterectomy and 73 cases and 137 controls reporting a tubal sterilisation. Validation rate for self-reported hysterectomy against medical reports (32 cases, 96 controls) was 96 per cent (95 per cent confidence interval (CI) 91 to 99) and for tubal sterilisation (32 cases, 77 controls) it was 88 per cent (CI 81 to 93), which is likely to be an underestimate. Although findings are based on small numbers of women for whom medical reports could be ascertained, they are consistent with other findings that suggest women have good recall of past histories of hysterectomy and tubal sterilisation; this allows long-term effects of these procedures to be studied with reasonable accuracy from self-reports.
- Published
- 1997
- Full Text
- View/download PDF
21. Breastfeeding, menopause, and epithelial ovarian cancer.
- Author
-
Siskind V, Green A, Bain C, and Purdie D
- Subjects
- Adult, Age of Onset, Australia epidemiology, Case-Control Studies, Confidence Intervals, Female, Humans, Incidence, Logistic Models, Middle Aged, Odds Ratio, Ovarian Neoplasms etiology, Ovarian Neoplasms prevention & control, Pregnancy, Risk Factors, Surveys and Questionnaires, Breast Feeding, Menopause physiology, Ovarian Neoplasms epidemiology
- Abstract
No previous study has examined the modifying effect of menopausal status on the association between lactation and ovarian cancer risk. We recruited 824 epithelial ovarian cancer cases and 855 community controls in three Australian states, collecting reproductive and lactation histories by means of a contraceptive calendar and pregnancy and breastfeeding record. We report results in women with at least one liveborn infant for unsupplemented breastfeeding, in line with a biological model linking suppression of ovulation to reduction in ovarian cancer risk. We derived odds ratios from multiple logistic regression models including number of liveborn children, age, age at first or last birth, and other potential confounders, overall and by menopausal status. Estimates of relative risk of ovarian cancer per month of full lactation were 0.99 [95% confidence interval (CI) = 0.97-1.00] overall and 1.00 (95% CI = 0.99-1.01) and 0.98 (95% CI = 0.95-1.01) among post- and premenopausal women, respectively. We tailored a lactation variable to the incessant ovulation hypothesis by progressively discounting breastfeeding the longer after birth it occurred, finding odds ratios similar to those for the unmodified duration variable. We found no association of note among postmenopausal women. Breastfeeding seems to be somewhat protective against ovarian cancer, but only before menopause.
- Published
- 1997
- Full Text
- View/download PDF
22. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations.
- Author
-
Chenevix-Trench G, Kerr J, Hurst T, Shih YC, Purdie D, Bergman L, Friedlander M, Sanderson B, Zournazi A, Coombs T, Leary JA, Crawford E, Shelling AN, Cooke I, Ganesan TS, Searle J, Choi C, Barrett JC, Khoo SK, and Ward B
- Subjects
- Female, Humans, Neoplasm Staging, Ovarian Neoplasms pathology, Survival Analysis, Chromosome Deletion, Genes, ras, Heterozygote, Mutation, Ovarian Neoplasms genetics
- Abstract
The molecular events that give rise to ovarian epithelial neoplasms are not well understood. In particular, it is not known whether adenocarcinomas arise from benign or low malignant potential (LMP) precursors. We have examined a large series of benign (25) and LMP (31) ovarian tumors for loss of heterozygosity (LOH) at multiple loci on 17 chromosomes. LOH was observed in benign tumors on chromosomes 6 (14%) and 9 (5%) and on the X chromosome (33%) only. LOH on these chromosomes was also detected in a small number of LMP neoplasms, suggesting that these may derive sometimes from benign precursors. In addition, we examined LOH in 93 adenocarcinomas. Analysis of associations between LOH events showed that LOH on chromosomes 5 and 17 (P = 0.0002) and on chromosomes 17 and 18 (P = 0.00007) were associated significantly with each other, which suggests that these may represent cooperative, progressive events. No novel significant associations were identified between LOH events and stage, grade, or histology, which would indicate the existence of genetic heterogeneity in ovarian neoplasms. KRAS2 mutations were detected more often in LMP neoplasms than in malignant tumors (P = 0.004) and were detected more often in Stage I/II malignant tumors than in Stage III/IV malignant tumors (P = 0.033), suggesting that LMP tumors with KRAS2 mutations are unlikely to progress to frank malignancy. Univariate (but not multivariate) survival analysis showed that LOH of chromosomes 11 (P = 0.039) and 17 (P = 0.04) was associated with a significantly worse prognosis. Replication of these novel findings is necessary, and the identification, isolation, and characterization of the critical genes affected by LOH will determine their importance in the pathogenesis of ovarian malignancies.
- Published
- 1997
- Full Text
- View/download PDF
23. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group.
- Author
-
Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P, and Susil B
- Subjects
- Adolescent, Adult, Aged, Australia epidemiology, Case-Control Studies, Educational Status, Epithelium pathology, Family Health, Female, Humans, Menstruation, Middle Aged, Multivariate Analysis, Parity, Risk Factors, Ovarian Neoplasms epidemiology, Reproduction
- Abstract
Of the few factors known to be associated with epithelial ovarian cancer, the most consistently observed relate to women's reproductive function, although even here uncertainties remain. We have undertaken a case-control study involving personal interviews with over 1,600 women, the largest of its kind to date, to investigate further the associations between women's reproductive histories and other factors and the development of ovarian cancer. Cases were drawn from women diagnosed with epithelial ovarian cancer in 3 Australian states, Queensland, New South Wales and Victoria, between August 1990 and December 1993, and controls were drawn at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed information about women's reproductive and contraceptive histories and other factors of interest, such as smoking and family history of ovarian or other cancer. Findings were based on data from 824 cases and 860 controls and confirmed the reduced risk of ovarian cancer associated with increasing parity and duration of use of the oral contraceptive pill (OCP), hysterectomy and tubal ligation. The strongest association of all was seen with use of the OCP for 10 years or more. An inverse association between ovarian cancer and age at first birth was observed, but this was not statistically significant. There were no associations between development of ovarian cancer and number of incomplete pregnancies, use of hormone replacement therapy or menstrual history. Among other factors considered, education after leaving school was negatively associated and high body mass index, family history of ovarian cancer, use of talc in the abdominal or perineal region and smoking were positively associated with occurrence of ovarian cancer.
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.